Gem Aromatics Ltd Q1 FY27 Earnings Analysis

- GEM Aromatics is focused on scaling high-value specialty products and improving utilization levels, especially at the Dahej facility. - The company expects FY ‘27 to perform closer to FY ‘25 levels, with better business momentum compared to FY ‘26 affected by geopolitical issues. - New capacity at Dahej has potential revenue of ~INR800 crores with gradual ramp-up planned, though full utilization guidance is expected by H2 FY ‘27. - The company is witnessing positive order flows and improving customer engagement, signaling recovery and growth. - Operating leverage benefits and product mix optimization are expected to support margin and profitability expansion. - Strategic investments and capabilities built over recent years position GEM Aromatics well for its next phase of growth and long-term value creation. - Near-term uncertainties due to geopolitical tensions and raw material volatility remain, but long-term fundamentals remain strong.

- FY ‘27 guidance is cautious due to geopolitical uncertainties and raw material price volatility; detailed guidance expected in 1-2 quarters. - Target consolidated revenue for FY ‘27 remains around INR 1,100 crores. - EBITDA margins aspirationally targeted at 16%-18% for FY ‘28, up from around 14% currently. - Operating leverage benefits expected from ramp-up at Dahej facility and improved utilization to support margin expansion. - Focus on scaling high-value specialty products and strengthening customer relations to drive sustainable growth. - Production ramp-up of new phenol-based products pending stabilization of raw material pricing. - Long-term growth underpinned by diversified product portfolio and expanding manufacturing capabilities. - Overall confidence in returning to or exceeding FY ‘25 performance levels as geopolitical issues resolve.

- Total planned capex for Dahej project is approximately INR 270 crores, with nearly INR 260 crores already incurred and substantially capitalized (Page 4). - The Dahej facility has commenced commercial production (Gemcool 5, Safranal) and is positioned for ramp-up during FY ‘27, with asset turnover expected around 3 to 3.5 times and peak revenue potential of about INR 800 crores (Pages 4, 5). - Further investments are focused on scaling high-value specialty products and strengthening global manufacturing capabilities, including multipurpose capacity for CRO, CMO, and CDMO services at Dahej (Pages 13, 15). - Plant readiness for phenol derivative production exists but actual ramp-up is delayed due to geopolitical uncertainties and raw material (phenol) price volatility; production expected to start once conditions stabilize (Pages 4, 7, 13). - Strategic investments over recent years position GEM Aromatics for sustainable growth and next phase of long-term value creation (Page 15).

- The transcript and presentation on page 15 do not mention any current or planned fundraising through debt or equity. - The company discusses ongoing strategic investments, particularly the Dahej facility capex (~INR 260-270 crores), which has been substantially capitalized. - No announcements or guidance are given regarding raising new capital via debt or equity. - Management focus remains on improving utilization, scaling products, and operational efficiencies rather than fundraising. - No responses to analyst questions indicate plans for equity or debt issuance in the near future. - Given the cautious stance on geopolitical uncertainty and market conditions, the company prefers to wait for more clarity before providing financial guidance, which also suggests no immediate fundraising plans.

- The company indicated improving business momentum with strong order and deal flows coming through, particularly after the Q4 FY26 dip. - Product qualification with distributors/traders globally is complete for new phenol-based products; distributors are ready to order once raw material prices stabilize. - There is a positive outlook on scaling up orders as tariffs issues ease and exports resume, especially to the U.S. market. - The Dahej facility has just gone live (April 2026), with ramp-up expected through FY27; exact utilization and order backlog figures will be clearer by H2 FY27. - Ongoing geopolitical and raw material price uncertainties (notably phenol) have delayed production start in some segments, impacting near-term order fulfillment. - Overall, management remains confident about sustained order flow and growth as market conditions stabilize and production capacity expands.